ENTA—As far as I can tell, the only thing that could be perceived as negative in ENTA's FY4Q15 PR and CC is the company's intention to spend $30-40M (about $7.5M per quarter) on R&D during FY2016.
All other aspects of ENTA's revenue and earnings are in ABBV's hands, and nothing on ENTA's CC contradicted anything that ABBV has already told investors.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”